Back
EME
Energy Metals Ltd
🇦🇺 ASX
⚡️ ENERGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-8.67%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Energy Metals Ltd. is an Australian uranium exploration company. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-09-09. The firm has eight exploration projects located in the Northern Territory (NT) and Western Australia covering around 2,400 square kilometers (km2). Its projects include Bigrlyi, Ngalia Regional, Macallan, Anketell, Mopoke Well, Lakeside, Manyingee, and Lake Mason. The Bigrlyi deposit is a sandstone hosted uranium-vanadium deposit located on the northern margin of the Ngalia Basin, approximately 350 km northwest of Alice Springs. The Ngalia Regional Project is located in the Ngalia Basin, between 180 and 350 km northwest of Alice Springs in the Northern Territory. The Macallan project comprises a single exploration licence application (ELA27333), located 460 km northwest of Alice Springs and 140 km from Bigrlyi. The Anketell project is located 100 km east of Mt. Magnet and comprises retention licence R58/2. The Manyingee project (E08/1480 and R08/3) is located 85 km south of the port of Onslow.
📈 Performance
Price History
-26.88%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.07
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in EME
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in EME
N/A
EME investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in EME also invest in...
Want more shares? Try these...
European Metals Holdings Ltd. engages in the development of the Cinovec lithium and tin project. The company is headquartered in Perth, Western Australia. The company went IPO on 2012-07-19. The firm focused on advancing the Cinovec vertically integrated battery metals project in Czech Republic. The Cinovec vertically integrated battery metals project is located 100 kilometers (km) northwest from Prague on the border with Germany, adjacent to a main road with two rail lines within 10 km of the deposit. The Cinovec vertically integrated battery metals project is situated in the Europe with access to end user car makers and companies involved in energy storage.
🙌 Performance (5Yr p.a)
-11.63%
📊 Share price
$0.18 AUD
⛏️ MINING
EMDN
Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. The company delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The firm is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.